© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 9, 652-661,
May 1, 2002
© 2002 Oxford University Press
REVIEW |
Adherence to Therapy With Oral Antineoplastic Agents
Affiliations of authors: A. H. Partridge, E. P. Winer, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; J. Avorn, P. S. Wang, Brigham and Women's Hospital and Harvard Medical School.
Correspondence to: Eric P. Winer, M.D., Breast Oncology Center, Dana-Farber Cancer Institute, Binney St., Boston, MA 02115 (e-mail: ewiner{at}partners.org).
With the rise in availability and increasing use of oral anticancer agents, concerns about adherence to prescribed regimens will become an increasingly important issue in oncology. Few published studies have focused on adherence to oral antineoplastic therapy, in part because the vast majority of chemotherapy is delivered intravenously in physicians' offices or hospitals. In this article, we review current knowledge of adherence behavior with regard to oral medications in general, including factors associated with adherence and methods for measuring adherence. We also review published studies of adherence to oral antineoplastic agents in adult and pediatric populations and adherence issues in cancer prevention. The available evidence reveals that patient adherence to oral chemotherapy recommendations is variable and not easily predicted. Adherence rates ranging from less than 20% to 100% have been reported, and certain populations, such as adolescents, pose particular challenges. Future efforts should focus on improving measurement and prediction of adherence and on developing interventions to improve adherence for both patients in clinical trials and patients being treated outside of the research setting. Assessment of adherence among individuals with cancer and implementation of interventions in situations of poor adherence should improve clinical outcomes.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. O. Jacobson, M. Polovich, K. K. McNiff, K. B. LeFebvre, C. Cummings, M. Galioto, K. R. Bonelli, and M. R. McCorkle American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards J. Clin. Oncol., November 10, 2009; 27(32): 5469 - 5475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Saif, A. Choma, S. J. Salamone, and E. Chu Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes J Natl Cancer Inst, October 19, 2009; (2009) djp328v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chan, Y. C. Leow, and M. H. Sim Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center Journal of Oncology Pharmacy Practice, September 1, 2009; 15(3): 161 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 M. N. Sitaresmi, S. Mostert, I. Purwanto, C. M. Gundy, Sutaryo, and A. J. P. Veerman Chemotherapy-Related Side Effects in Childhood Acute Lymphoblastic Leukemia in Indonesia: Parental Perceptions Journal of Pediatric Oncology Nursing, July 1, 2009; 26(4): 198 - 207. [Abstract] [PDF]
|
|
|
|
 |
|
 E. H. Tan, J. Rolski, T. Grodzki, C. P. Schneider, U. Gatzemeier, P. Zatloukal, E. Aitini, G. Carteni, H. Riska, Y. H. Tsai, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer Ann. Onc., July 1, 2009; 20(7): 1249 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Moynihan, A. R. Norman, Y. Barbachano, L. Burchell, R. Huddart, D. P. Dearnaley, and A. Horwich Prospective Study of Factors Predicting Adherence to Medical Advice in Men With Testicular Cancer J. Clin. Oncol., May 1, 2009; 27(13): 2144 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ruddy, E. Mayer, and A. Partridge Patient adherence and persistence with oral anticancer treatment CA Cancer J Clin, January 1, 2009; 59(1): 56 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. Partridge, P. M. Kato, and A. DeMichele Adherence to Oral Cancer Therapies: Challenges and Opportunities ASCO Educational Book, January 1, 2009; 2009(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Kato, S. W. Cole, A. S. Bradlyn, and B. H. Pollock A Video Game Improves Behavioral Outcomes in Adolescents and Young Adults With Cancer: A Randomized Trial Pediatrics, August 1, 2008; 122(2): e305 - e317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Patton Increased Use of Oral Chemotherapy Drugs Spurs Increased Attention to Patient Compliance J. Oncol. Pract, July 1, 2008; 4(4): 175 - 177. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Chisholm-Burns and C. A. Spivey Pharmacoadherence: A new term for a significant problem Am. J. Health Syst. Pharm., April 1, 2008; 65(7): 661 - 667. [Full Text] [PDF]
|
|
|
|
|
|
A. H. Partridge, A. LaFountain, E. Mayer, B. S. Taylor, E. Winer, and A. Asnis-Alibozek Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer J. Clin. Oncol., February 1, 2008; 26(4): 556 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann. Onc., February 1, 2008; 19(2): 212 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Viele Managing oral chemotherapy: The healthcare practitioner's role Am. J. Health Syst. Pharm., May 1, 2007; 64(9_Supplement_5): S25 - S32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N Weingart, J. Flug, D. Brouillard, L. Morway, A. Partridge, S. Bartel, L. N Shulman, and M. Connor Oral chemotherapy safety practices at US cancer centres: questionnaire survey BMJ, February 24, 2007; 334(7590): 407 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baweja, V. J. Suman, T. R. Fitch, J. A. Mailliard, A. Bernath, K. M. Rowland, S. R. Alberts, J. S. Kaur, and E. A. Perez Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients >=65 years of age: an NCCTG study Ann. Onc., April 1, 2006; 17(4): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Partridge Non-adherence to endocrine therapy for breast cancer Ann. Onc., February 1, 2006; 17(2): 183 - 184. [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Kohne and G. Folprecht On prejudice and facts and choices Ann. Onc., February 1, 2006; 17(2): 185 - 187. [Full Text] [PDF]
|
|
|
|
|
|
L. Fallowfield, L. Atkins, S. Catt, A. Cox, C. Coxon, C. Langridge, R. Morris, and M. Price Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer Ann. Onc., February 1, 2006; 17(2): 205 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Andersen, W. B. Farrar, D. M. Golden-Kreutz, R. Glaser, C. F. Emery, T. R. Crespin, C. L. Shapiro, and W. E. Carson III Psychological, Behavioral, and Immune Changes After a Psychological Intervention: A Clinical Trial J. Clin. Oncol., September 1, 2004; 22(17): 3570 - 3580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L de Lemos, L. John, L. Nakashima, R. K. O'Brien, and S. C. Taylor Advising Cancer Patients on Natural Health Products--A Structured Approach Ann. Pharmacother., September 1, 2004; 38(9): 1406 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Conte and V. Guarneri Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens Oncologist, September 1, 2004; 9(suppl_4): 28 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli, and R. A. Silliman Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor--Positive Breast Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3309 - 3315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. R. O'Brien, A. Szczesna, H. Karnicka, P. Zatloukal, T. Eisen, W. Hartmann, P. Kasan, B. Longerey, and F. Lefresne Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: results of a multicentre phase II study Ann. Onc., June 1, 2004; 15(6): 921 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Partridge, P. S. Wang, E. P. Winer, and J. Avorn Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer J. Clin. Oncol., February 15, 2003; 21(4): 602 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. de Lemos Re: Adherence to Therapy With Oral Antineoplastic Agents J Natl Cancer Inst, November 6, 2002; 94(21): 1652 - 1652. [Full Text] [PDF]
|
|
|
|
|
|
E. Fox, G. A. Curt, and F. M. Balis Clinical Trial Design for Target-Based Therapy Oncologist, October 1, 2002; 7(5): 401 - 409. [Abstract] [Full Text] [PDF]
|
|